Journal of Neuroinfectious Diseases
Open Access

The co-occurrence of HIV-1 infection and alcohol misuse presents a formidable challenge to global public health, necessitating a comprehensive understanding of the synergistic effects on the central nervous system (CNS). While the primary impact of HIV-1 is on the immune system, the virus also penetrates the CNS, leading to various neurological complications [1]. When compounded by alcohol misuse, a known neurotoxin, the consequences become even more pronounced. This paper aims to elucidate the causes of neurodegeneration and subsequent neurocognitive impairment resulting from the dual burden of HIV-1 infection and alcohol misuse. The intricate interplay between HIV-1 and alcohol involves complex molecular and cellular mechanisms that contribute to the observed neuropathological changes. Neuroinflammation, oxidative stress, and dysregulation of neurotransmitter systems are among the key factors driving neurodegeneration in individuals with concurrent HIV- 1 infection and alcohol misuse [2-4]. Moreover, the compromised blood-brain barrier exacerbates the entry of both HIV-1 and alcohol into the CNS, intensifying their detrimental effects. In addition to understanding the pathophysiology, this review explores current treatment options and potential therapeutic strategies to address the neurological consequences of this dual burden. As the global incidence of HIV-1 infection and alcohol misuse continues to rise, a deeper comprehension of the underlying mechanisms and effective interventions is imperative for improving the overall well-being of affected individuals. One quarter of adults and 50% of children used to develop significant neurocognitive complications as a consequence of infection at a period of immunosuppression or AIDS before the introduction of anti-retroviral therapy (ART). While subclinical metabolic and structural abnormalities are detectable in neurologically asymptomatic subjects, overt HAD usually develops as a late complication and is accompanied by immunosuppression. Reduction of the neuronal marker, N-acetylaspartate, in frontal lobe white and gray matter was found in individuals taking NRTIs, didanosine and/or stavudine, as a result of depleted brain mitochondria and/or alterations in cellular respiration. Introduction of ART considerably changed the clinical evolution of HIV-1 infection. ART diminished the incidence and prevalence of major opportunistic infections and resulted in improvement in survival rates. Patients (10-15%) are now over 50 years of age and, with continued advances in treatment, many will reach normal life expectancy [5-8].

Conclusion

In conclusion, the dual burden of HIV-1 infection and alcohol misuse presents a multifaceted challenge that significantly impacts the neurological health of affected individuals. The intricate interplay between these two factors contributes to neurodegeneration and subsequent neurocognitive impairment through a complex web of molecular and cellular mechanisms. Understanding these processes is critical for developing targeted interventions that address the unique challenges posed by this co-occurrence. As research in this field progresses, it is imperative to continue investigating novel therapeutic targets and refining existing treatment modalities. Moreover, addressing the socio-economic factors contributing to HIV-1 infection and alcohol misuse is crucial for developing holistic and effective public health strategies. In essence, unraveling the complexities of HIV- 1 infection with alcohol misuse and its impact on neurodegeneration and neurocognitive impairment opens new avenues for targeted interventions. By advancing our understanding of these mechanisms, we pave the way for improved patient outcomes and a better quality of life for those affected by this challenging dual burden.

Acknowledgment

None

Conflict of Interest

None

1. Palmer BW, Heaton SC, Jeste DV (1999) Older patients with schizophrenia: challenges in the coming decades.Psychiatric Services 50: 1178–1183.

Google Scholar, Crossref, Indexed at

2. Patorno E, Bohn R, Wahl P, Avorn J, Patrick AR, et al. (2010) Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death.JAMA 303: 1401–1409.

Google Scholar, Crossref, Indexed at

3. Olesen JB, Hansen PR, Erdal J, Abildstrøm SZ, Weeke P, et al. (2010) Antiepileptic drugs and risk of suicide: a nationwide study.Pharmacoepidem Dr S 19: 518–524.

Google Scholar, Crossref, Indexed at

4. Leipzig R, Cumming R, Tinetti M (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs.J Am Geriatr Soc 47: 30–39.

Google Scholar, Crossref, Indexed at

5. Gill S, Bronskill S, Normand S, Anderson GM, Sykora K, et al. (2007) Antipsychotic drug use and mortality in older adults with dementia.Ann Intern Med 146: 775–786.

Google Scholar, Crossref, Indexed at

6. Casey D, Haupt D, Newcomer J, Henderson DC, Sernyak MJ, et al. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.J Clin Psychiatry 65(Suppl 7): 4–18.

Google Scholar, Indexed at

7. Schneider LS, Dagerman KS, Insel P (2005) Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia.JAMA 294: 1934–1943.

Google Scholar, Crossref, Indexed at

8. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, et al. (2004) Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants.Arch Intern Med 164: 2367–2370.

Google Scholar, Crossref, Indexed at